@article {Serrano2021.02.15.21251511, author = {Geidy E. Serrano and Jessica E. Walker and Richard Arce and Michael J. Glass and Daisy Vargas and Lucia I. Sue and Anthony J. Intorcia and Courtney M. Nelson and Javon Oliver and Jaclyn Papa and Aryck Russell and Katsuko E. Suszczewicz and Claryssa I. Borja and Christine Belden and Danielle Goldfarb and David Shprecher and Alireza Atri and Charles H. Adler and Holly A. Shill and Erika Driver-Dunckley and Shyamal H. Mehta and Benjamin Readhead and Matthew J. Huentelman and Joseph L. Peters and Ellie Alevritis and Christian Bimi and Joseph P. Mizgerd and Eric M. Reiman and Thomas J. Montine and Marc Desforges and James L. Zehnder and Malaya K. Sahoo and Haiyu Zhang and Daniel Solis and Benjamin A. Pinsky and Michael Deture and Dennis W. Dickson and Thomas G. Beach}, title = {Mapping of SARS-CoV-2 Brain Invasion and Histopathology in COVID-19 Disease}, elocation-id = {2021.02.15.21251511}, year = {2021}, doi = {10.1101/2021.02.15.21251511}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The coronavirus SARS-CoV-2 (SCV2) causes acute respiratory distress, termed COVID-19 disease, with substantial morbidity and mortality. As SCV2 is related to previously-studied coronaviruses that have been shown to have the capability for brain invasion, it seems likely that SCV2 may be able to do so as well. To date, although there have been many clinical and autopsy-based reports that describe a broad range of SCV2-associated neurological conditions, it is unclear what fraction of these have been due to direct CNS invasion versus indirect effects caused by systemic reactions to critical illness. Still critically lacking is a comprehensive tissue-based survey of the CNS presence and specific neuropathology of SCV2 in humans. We conducted an extensive neuroanatomical survey of RT-PCR-detected SCV2 in 16 brain regions from 20 subjects who died of COVID-19 disease. Targeted areas were those with cranial nerve nuclei, including the olfactory bulb, medullary dorsal motor nucleus of the vagus nerve and the pontine trigeminal nerve nuclei, as well as areas possibly exposed to hematogenous entry, including the choroid plexus, leptomeninges, median eminence of the hypothalamus and area postrema of the medulla. Subjects ranged in age from 38 to 97 (mean 77) with 9 females and 11 males. Most subjects had typical age-related neuropathological findings. Two subjects had severe neuropathology, one with a large acute cerebral infarction and one with hemorrhagic encephalitis, that was unequivocally related to their COVID-19 disease while most of the 18 other subjects had non-specific histopathology including focal β-amyloid precursor protein white matter immunoreactivity and sparse perivascular mononuclear cell cuffing. Four subjects (20\%) had SCV2 RNA in one or more brain regions including the olfactory bulb, amygdala, entorhinal area, temporal and frontal neocortex, dorsal medulla and leptomeninges. The subject with encephalitis was SCV2-positive in a histopathologically-affected area, the entorhinal cortex, while the subject with the large acute cerebral infarct was SCV2-negative in all brain regions. Like other human coronaviruses, SCV2 can inflict acute neuropathology in susceptible patients. Much remains to be understood, including what viral and host factors influence SCV2 brain invasion and whether it is cleared from the brain subsequent to the acute illness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by a COVID-19 Supplement to a National Institute on Aging grant, (3P30AG019610-20S1), to the Arizona Alzheimer Disease Core Center, submitted in response to a Notice of Special Interest (NOSI) issued by the National Institute on Aging (NOT-AG-20-022).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Subjects were enrolled in one of two separate Institutional Review Board (IRB) approved protocols reviewed by the Western IRB in Puyallup, Washington.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request. https://www.brainandbodydonationprogram.org}, URL = {https://www.medrxiv.org/content/early/2021/02/18/2021.02.15.21251511}, eprint = {https://www.medrxiv.org/content/early/2021/02/18/2021.02.15.21251511.full.pdf}, journal = {medRxiv} }